Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Free Report) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Inovio Pharmaceuticals in a report released on Monday, June 1st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will earn ($0.24) per share for the year. HC Wainwright has a “Neutral” rating and a $2.50 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.98) per share.
Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02.
Check Out Our Latest Stock Report on Inovio Pharmaceuticals
Inovio Pharmaceuticals Price Performance
Inovio Pharmaceuticals stock opened at $1.28 on Tuesday. The stock has a market capitalization of $105.31 million, a PE ratio of -0.88 and a beta of 1.49. The business has a 50 day simple moving average of $1.29 and a 200-day simple moving average of $1.62. Inovio Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.98.
Institutional Trading of Inovio Pharmaceuticals
Large investors have recently added to or reduced their stakes in the stock. Boxer Capital Management LLC acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $5,382,000. Millennium Management LLC grew its holdings in shares of Inovio Pharmaceuticals by 468.7% in the 3rd quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock worth $4,616,000 after acquiring an additional 1,625,653 shares during the last quarter. Eversept Partners LP acquired a new stake in Inovio Pharmaceuticals during the 1st quarter valued at $1,802,000. Vanguard Group Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after purchasing an additional 703,727 shares during the period. Finally, GSA Capital Partners LLP grew its stake in Inovio Pharmaceuticals by 171.4% in the third quarter. GSA Capital Partners LLP now owns 443,104 shares of the biopharmaceutical company’s stock valued at $1,037,000 after purchasing an additional 279,844 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
See Also
- Five stocks we like better than Inovio Pharmaceuticals
- Why 1 Little-Known ETF Is Riding the AI Chip Shortage
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
